Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$182.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vimal D. Mehta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- 0.29
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -46.97
Financials
Revenue
$182.0K+32.8%Net Income
$-14.71MEBITDA
$-10.44MFree Cash Flow
$-6.10MEPS (diluted)
$-1.21Shares Outstanding (diluted)
12.21M+1086.4%Operating Expenses
$10.35MCash & Debt
$12.84MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $642.0K | $-69.90M | $-5.73 |
| 2024 | $2.27M | $-59.60M | $-23.51 |
| 2023 | $1.38M | $-179.05M | $-98.35 |
| 2022 | $375.0K | $-165.76M | $-94.67 |
| 2021 | $0.00 | $-106.93M | $-64.87 |
| 2020 | $0.00 | $-82.17M | $-60.63 |
| 2019 | $0.00 | $-32.34M | $-32.38 |
| 2018 | $0.00 | $-19.27M | $-21.16 |
| 2017 | $0.00 | $-4.54M | $-4.41 |
| 2016 | $0.00 | $-2.12M | $-2.06 |
| 2015 | $0.00 | $-636.0K | $-0.64 |
Valuation
BTAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·39d ago·Negative
…itment for debtor-in-possession (DIP) financing to support ongoing operations NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH (“Teva”), a subsidiary of Teva Pharmaceutical Industri…
View source ↗ - Newsreuters.com·39d ago·Negative
Biopharma firm BioXcel Therapeutics files for bankruptcy in US AI-driven biopharma firm BioXcel Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. on Thursday.
View source ↗ - Newszacks.com·53d ago·Negative
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $2.45 per share a year ago.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.01 per share
Typical surprise -6.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.49 vs $-0.44miss
- Fri, May 15$-0.54 vs $-0.59beat
- Thu, Mar 26$-0.58 vs $-0.34miss
- Wed, Nov 12$-2.18 vs $-1.54miss
- Tue, Aug 12$-2.45 vs $-2.30miss
- Mon, May 12$-1.50 vs $-2.72beat
Estimates and results for BTAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BTAI officers and directors.
- Bought
- —
- Sold
- $43k
0 trades
4 trades
- Yocca Franksold
- Rodriguez Javiersold
- Steinhart Richard Isold
- Mehta Vimalsold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BTAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.